Sugi Predict

Sugi Predict / Compounds / SCHEMBL29531990

SCHEMBL29531990

SCHEMBL29531990

CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)O)[C@@H](C)O)[C@@H](C)CC

nearest known ligand 0.77

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PTH1R Q03431 5/20 0.77
▸ VIPR1 P32241 5/20 0.72
▸ VIPR2 P41587 7/20 0.70
▸ GLP1R P43220 5/20 0.70
▸ ECE1 P42892 1/20 0.70
▸ MUS81 Q96NY9 1/20 0.70
▸ CCKBR P32239 1/20 0.67
▸ NPY2R P49146 2/20 0.65
▸ NPY4R P50391 2/20 0.65
▸ NPY5R Q15761 2/20 0.65
▸ NPY1R P25929 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29569801 0.91 VIPR1 (0.79) PTH1RVIPR1VIPR2GLP1RECE1
SCHEMBL29389724 0.91 VIPR1 (0.79) PTH1RVIPR1VIPR2GLP1RECE1
SCHEMBL30495732 0.90 VIPR1 (0.66) PTH1RVIPR1VIPR2GLP1RECE1
SCHEMBL29379965 0.89 PTH1R (0.74) PTH1RVIPR1GLP1RECE1MUS81
SCHEMBL28214439 0.89 PTH1R (0.74) PTH1RVIPR1GLP1RECE1MUS81
SCHEMBL15182424 0.89 GLP1R (0.69) PTH1RVIPR1VIPR2GLP1RECE1
Scyllatoxin SCHEMBL29388554 0.89 PTH1R (0.74) PTH1RVIPR1VIPR2GLP1RCCKBR
SCHEMBL4329513 0.89 VIPR1 (0.78) PTH1RVIPR1VIPR2GLP1RECE1
SCHEMBL30495814 0.89 VIPR1 (0.71) PTH1RVIPR1VIPR2GLP1RECE1
SCHEMBL29382033 0.89 GLP1R (0.78) PTH1RVIPR1VIPR2GLP1RECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130972-A1 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS RADIUS HEALTH, INC. (US) 2026-05-14 — — US disclosed
EP-4719459-A1 METHODS FOR IDENTIFICATION AND QUANTITATION OF ABALOPARATIDE AND RELATED PEPTIDE IMPURITIES Radius Health, Inc. (US) 2026-04-08 — — EP disclosed
US-20250334560-A1 ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME RADIUS HEALTH, INC. (US) 2025-10-30 — — US disclosed
US-20250268989-A1 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS RADIUS HEALTH, INC. (US) 2025-08-28 — — US disclosed
US-20250231166-A1 ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME RADIUS HEALTH, INC. (US) 2025-07-17 — — US disclosed
US-20250076270-A1 ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME RADIUS HEALTH, INC. (US) 2025-03-06 — — US disclosed
CN-119280383-A Oral water-soluble polypeptide pharmaceutical composition and preparation method thereof 齐鲁制药有限公司 2025-01-10 — — CN disclosed
WO-2024246840-A1 METHODS FOR IDENTIFICATION AND QUANTITATION OF ABALOPARATIDE AND RELATED PEPTIDE IMPURITIES RADIUS HEALTH, INC. (US) 2024-12-05 — — WO disclosed
CN-119053341-A Recombinant antibodies, pharmaceutical compositions comprising the same and their use in the treatment of cancer 智合精准医学科技股份有限公司 2024-11-29 — — CN disclosed
US-20240374689-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME LONGEVITY BIOTECH, INC. 2024-11-14 — — US disclosed
US-20230330191-A1 METHODS OF STIMULATING BONE GROWTH WITH ABALOPARATIDE AND DENOSUMAB RADIUS HEALTH, INC. (US) 2023-10-19 — — US disclosed
US-11787876-B2 Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof XOMA (US) LLC (US) 2023-10-17 — — US disclosed
US-11782041-B2 Abaloparatide formulations and methods of testing, storing, modifying, and using same RADIUS HEALTH, INC. (US) 2023-10-10 — — US disclosed
US-20230280324-A1 ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME RADIUS HEALTH, INC. (US) 2023-09-07 — — US disclosed
WO-2023080159-A1 LIGAND-BOUND NUCLEIC ACID COMPLEX レナセラピューティクス株式会社 2023-05-11 — — WO disclosed
US-20230053463-A1 ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME RADIUS HEALTH, INC. (US) 2023-02-23 — — US disclosed
US-20220378881-A1 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS RADIUS HEALTH, INC. (US) 2022-12-01 — — US disclosed
US-20220289812-A1 ELP FUSION PROTEINS COMPRISING PARATHYROID HORMONE FOR CONTROLLED AND SUSTAINED RELEASE Immunoforge Co., Ltd. (KR) 2022-09-15 — — US disclosed
US-20220177513-A1 Process for the Preparation of Abaloparatide MYLAN LABORATORIES LIMITED (IN) 2022-06-09 — — US disclosed
US-20220133857-A1 ORAL FORMULATION AND TREATMENT OF PTH ANALOG ANYA BIOPHARM INC. (TW) 2022-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260130972-A1 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS SOST, PTH1R, SHBG PTH1R 2/4885VIPR1 1610/4885VIPR2 1275/4885
US-20220177513-A1 Process for the Preparation of Abaloparatide GLP1R, IAPP, GCGR PTH1R 373/4885VIPR1 1425/4885VIPR2 1171/4885
US-20240374689-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME SCTR, GIPR, APLNR PTH1R 306/4885VIPR1 67/4885VIPR2 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.